Sanofi stock holds steady as India unit navigates vaccine supply shift

Sanofi stock in India is trading slightly lower as of September 1, 2026, while the company manages a flu vaccine supply shortfall in South Korea and maintains a solid market capitalization and mutual fund backing.

Sanofi India Ltd. stock (ISIN INE058A01010) is trading at a moderate discount to its recent levels, with the share price at INR 3,124.00 as of August 31, 2026, on the National Stock Exchange, compared with a previous close of INR 3,181.60.

Flu vaccine supply shift highlights operational challenges

According to a report by Chosun Biz dated September 1, 2026, Sanofi's flu vaccine supply to South Korea's National Immunization Program has declined to 1.75 million doses for the current season. In response, domestic producer GC Biopharma has expanded its contribution by 500,000 doses, bringing its total supply for the program to 3.16 million doses. For investors, this shift underscores how regional supply constraints can redirect demand to competitors and potentially influence Sanofi India’s long-term vaccine positioning in Asia.

Recent share price and market capitalization

Market data from Upstox show that Sanofi India shares closed at INR 3,124.00 on August 31, 2026, down 1.81 percent from the previous close of INR 3,181.60. As of the same date, the company’s market capitalization stood at INR 8,111.74 crore, reflecting the value the market currently assigns to its Indian operations. The stock opened at INR 3,181.70 on August 31, 2026, illustrating that intraday selling pressure pushed the price below the opening level by the close.

The same Upstox data indicate that mutual funds held 9.14 percent of Sanofi India’s shares at the end of June 2026, a sign that institutional investors maintain a meaningful presence in the stock. For retail investors, such holdings often provide a degree of confidence that professional investors are willing to commit capital to the company’s long-term story.

Corporate profile and product focus in India

Sanofi India primarily operates as a pharmaceuticals company, distributing prescription medicines and vaccines in the Indian market under the broader global Sanofi brand. In addition to vaccines, the portfolio includes therapies in areas such as diabetes, cardiovascular disease and specialty care, making the company an important player in India’s healthcare sector. The connection to the global Sanofi group means that developments in international vaccine supply, such as the South Korean flu program shift, can have indirect strategic implications for Sanofi India, even if the short-term financial impact is limited.

Sanofi India stock on NSE and BSE

Sanofi India is listed on the National Stock Exchange under the ticker SANOFI and on the Bombay Stock Exchange under the code 500674, with the ISIN INE058A01010 confirmed by the Upstox profile. The NSE quote of INR 3,124.00 as of August 31, 2026, represents the most recent closing price available for investors tracking the stock. With a market capitalization of INR 8,111.74 crore at that date, Sanofi India stands among the mid-cap pharmaceutical names in the Indian market rather than the largest large-cap peers.

Sanofi India key data

• Company: Sanofi India Ltd.
• ISIN: INE058A01010
• Ticker: SANOFI
• Trading venue: NSE India
• Price (as of August 31, 2026): 3,124.00 INR
• Market capitalization: 8,111.74 crore INR (as of August 31, 2026)
• Sector / Industry: Pharmaceuticals
• Index membership: Local Indian indices